Welcome to our dedicated page for Haleon plc SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Haleon plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Haleon plc's regulatory disclosures and financial reporting.
On 11 July 2025, Haleon plc (LSE/NYSE: HLN) disclosed a TR-1 major shareholding notification from Wellington Management Group LLP. The investment manager’s aggregated interest fell from 5.87 % to 5.29 % of Haleon’s voting rights as of 10 July 2025, comprising 4.97 % held directly through ordinary shares (446.9 m votes) and 0.32 % via financial instruments (predominantly depository receipts and small equity swaps). The absolute position equals 475.6 m voting rights.
The reduction keeps Wellington above the critical UK 5 % disclosure threshold but signals incremental selling. No operational or earnings data are included; the filing is purely ownership-related.
Haleon plc (NYSE/LSE: HLN) has released unaudited historic pro-forma financials that restate 2023-2025 revenue under a new six-category reporting framework. The change, first signalled at the 1 May 2025 Capital Markets Day, splits the former “Digestive Health & Other” segment into two lines—Digestive Health and Therapeutic Skin Health & Other—and moves the Smokers Health franchise into Respiratory Health. Beginning with the Half-Year results on 31 July 2025, Haleon will report:
- Oral Health
- Vitamins, Minerals & Supplements (VMS)
- Pain Relief
- Respiratory Health
- Digestive Health
- Therapeutic Skin Health & Other
Key restated figures (FY 2024 vs FY 2023):
- Total revenue £11.23 bn, down 0.6%; organic revenue growth +5.0%
- Oral Health £3.31 bn (+5.6% reported, +9.6% organic) – strongest absolute contributor
- VMS £1.70 bn (+3.4% reported, +7.6% organic) – solid rebound from 0.9% organic in 2023
- Pain Relief £2.56 bn (-3.3% reported, +0.1% organic) – softness after 7.4% organic in 2023
- Respiratory Health £2.12 bn (-5.4% reported, +1.0% organic) – lapping strong 2023 cold/flu season
- Digestive Health £1.03 bn (+1.7% reported, +5.5% organic)
- Therapeutic Skin Health & Other £0.51 bn (-17.5% reported, +9.8% organic) – large FX/disposal drag
Q1 2025 restated revenue shows modest momentum: total £2.85 bn (-2.3% reported, +3.5% organic) with Oral Health (+3.0% reported) and Pain Relief (-0.2% reported, +2.6% organic) leading. Geographical splits are unchanged and no guidance is updated in this filing.
The recast enhances transparency around category-level trends and is intended to align external reporting with strategic growth priorities ahead of Haleon’s first standalone medium-term targets expected at H1 results.
Haleon plc (LSE/NYSE: HLN) filed a Form 6-K reporting progress on the share buyback programme announced 28 March 2025.
Daily trade: on 25 June 2025 the company repurchased 1,006,111 ordinary shares at a volume-weighted average price of 383.38 pence (high 384.80 p, low 380.70 p). All shares will be cancelled.
Completion of first tranche: Haleon has now finished the programme’s first tranche, acquiring 51,036,522 shares for an aggregate consideration of about £200 million. The tranche equates to roughly 0.6 % of the current share base.
Updated share capital: issued share capital is 8,988,533,553 shares of £0.01 each. After deducting 4,080,205 treasury shares, voting shares total 8,984,453,348. Investors should use this figure for FCA disclosure-threshold calculations.
Next steps: management will announce any further tranches separately. The filing contains no earnings, guidance, or operational updates.
Haleon has announced a significant share buyback transaction as part of its program launched on March 28, 2025. On June 23, 2025, the company purchased 1,008,610 ordinary shares for cancellation at prices ranging from 381.50p to 387.90p per share, with a volume-weighted average price of 385.10p.
Following the transaction, Haleon's registered share capital consists of 8,990,548,799 ordinary shares, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,986,468,594, a figure relevant for shareholder disclosure requirements under FCA regulations.
Haleon, a global consumer health leader listed on LSE/NYSE (HLN), maintains a portfolio across six major categories including Oral Health, VMS, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Key brands include Advil, Centrum, Sensodyne, and Voltaren.
Haleon has announced a significant share buyback transaction as part of its program announced on March 28, 2025. On June 20, 2025, the company purchased 1,016,186 ordinary shares for cancellation at prices ranging from 382.70p to 388.00p per share, with a volume-weighted average price of 385.10p.
Following the settlement, Haleon's registered share capital consists of 8,991,557,409 ordinary shares of £0.01 each, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,987,477,204.
Haleon, a global consumer health leader listed on LSE/NYSE, maintains a portfolio across six major categories:
- Oral Health
- Vitamins, Minerals and Supplements (VMS)
- Pain Relief
- Respiratory Health
- Digestive Health
- Therapeutic Skin Health
The company's brand portfolio includes notable names such as Advil, Centrum, Sensodyne, and Voltaren.